Trade Pfizer ^PFE

From Baric's Blueprint to SV40 and Back Again

Artemis Investment Management LLP Sells 3,850,879 Shares of Pfizer Inc. $PFE - Zolmax

Pfizer Inc. $PFE Holdings Lifted by Quintet Private Bank Europe S.A.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) Could Be 3% Below Fair Value After Fresh TUKYSA FDA Approval

Artemis Investment Management LLP Sells 3,850,879 Shares of Pfizer Inc. $PFE - Daily Political

Pfizer Is Just One Of These 3 AI Healthcare Stocks

Pfizer (PFE) Wins TUKYSA Approval And LITFULO Data, Is It Still 3% Undervalued?

FDA Approves Pfizer's TUKYSA Regimen For Front-Line HER2+ Breast Cancer Maintenance

Pfizer (NYSE:PFE) Given New $28.00 Price Target at Cantor Fitzgerald - Daily Political

Pfizer's TUKYSA Gets FDA Nod For Front-Line HER2+ Breast Cancer Maintenance

Fake pharma racket sourced Pfizer labels from Turkiye: SIT | India News

AI Breakthrough: Room Temperature Storage for mRNA Vaccines, ETPharma

Pfizer Job Cuts Italy: Pfizer to Lay Off 330 Workers at Sicily Plant Amid Industry Cuts, ETHRWorld

Combined limbal dysmaturation and microcyst like epithelial changes with corneal nerve alterations of a novel anti nectin-4-MMAE antibody drug conjugate

Canandaigua National Trust Co of Florida Purchases New Shares in Pfizer Inc. $PFE - Zolmax

Canandaigua National Trust Co of Florida Buys New Position in Pfizer Inc. $PFE

Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?

Pfizer (PFE) Trades Below Its Own Average Multiple, Is It Cheap for a Reason?

Pfizer Gets FDA Approval for Expanded Use of Breast-Cancer Treatment Tukysa | Morningstar

Pfizer (NYSE:PFE) Stock Price Up 1.7% After Dividend Announcement - Stock Observer

Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer | Morningstar

Pfizer (PFE) Posted Positive Phase 3 Vitiligo Results For LITFULO

Pfizer Inc. (NYSE:PFE) Shareholders to Collect $0.43 Quarterly Dividend - Zolmax

Pfizer Inc. (NYSE:PFE) Shareholders Set to Receive $0.43 Quarterly Dividend

Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy. - AOL

Johnson & Johnson $JNJ Stock Holdings Cut by Hall Laurie J Trustee - Markets Daily

Is Pfizer (PFE) a Good or Bad Investment at Today's Price?

5,446 Shares in Johnson & Johnson $JNJ Bought by Eleva Capital SAS - Zolmax

Johnson & Johnson $JNJ Shares Newly Purchased by Eleva Capital SAS

Pfizer Declares $0.43 Fourth-Quarter Dividend For Shareholders

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

Johnson & Johnson $JNJ Shares Sold by Iowa State Bank - Daily Political

Pfizer (NYSE:PFE) Stock Price Down 1.4% - What's Next?

Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes

Pfizer (NYSE:PFE) Stock Falls 1.4% - Should You Sell? - Daily Political

Vaxcyte skyrockets on 'near best-case' pneumococcal vaccine data

Pfizer describes new APLNR agonists

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.

Best Pharmaceutical Stocks To Add to Your Watchlist - October 4th - Stock Observer

COPD trial wins spur broad respiratory hopes

Pay Me While I Wait: 3 Turnaround Stocks That Keep Paying Investors Through the Rebuild

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Reviewing Verastem (NASDAQ:VSTM) and Nektar Therapeutics (NASDAQ:NKTR) - Markets Daily

Pfizer (PFE) and Its Rivals Critical Comparison - Markets Daily

Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax

Pfizer (PFE) Receives a Hold from Leerink Partners

Fake drug probe: Karnataka FDA seeks Pfizer intervention on fake antibiotics

3 AI Healthcare Stocks With Earnings Growth Up To 15%

Pfizer (NYSE:PFE) Shares Down 1.1% - Time to Sell?

Pfizer Sues Sun Pharmaceutical to Block Copies of Cancer Drug

'They knew about myocarditis in kids, yet…': Florida sues Pfizer over 'deceptive COVID Vaccine lies' - The Economic Times Video | ET Now

Novartis taps Abogen's RNA platform in potential $7.8B deal

PFE: Pricing Pressure Still Matters, Pipeline Execution Now Carries The Bear Case

Florida AG sues Pfizer, CEO over COVID-19 vaccine safety claims

Florida Attorney General Files Lawsuit Against Pfizer Over COVID-19 Vaccine Safety Claims, ETPharma

Pfizer (NYSE:PFE) Stock Falls 1.5% - What's Next? - Markets Daily

Pfizer (NYSE:PFE) Stock Falls 1.5% - Time to Sell?

Pfizer-Sankar Foundation eye camp screens 1,113 patients

'Deceptively marketing the products as safe': Pfizer sued for deceiving public about COVID shots

Florida sues Pfizer over Covid-19 vaccine safety claims

Does Pfizer (PFE) Have A New Growth Driver In Tilrekimig?

Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment | Morningstar

Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water

6 High-Yield Stocks Where the Market May Be Warning of a Dividend Cut

Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut

Pfizer's Tilrekimig Delivers Significant Skin Clearance In Phase 2 Atopic Dermatitis Study

Pfizer's Tilrekimig Meets Phase 2 Primary Endpoint In Atopic Dermatitis

Lyme Disease Market: Steady Growth Ahead as Vaccine Candidates and Novel Preventive Therapies Advance Through 2034 | ABNewswire

Pfizer CEO Albert Bourla on AI and the future of medicine

Promising Pharmaceutical Stocks Worth Watching - September 30th

Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat

Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson

Analyzing Perrigo (NYSE:PRGO) and Pfizer (NYSE:PFE) - Stock Observer

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire

Carlyle Wins Dispute Over AI Platform Linked to Pfizer Covid Vax

Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Comparing Pfizer (PFE) & The Competition - Daily Political

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Sickle Cell Disease Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments - DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma | ABNewswire

Aplastic Anemia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 - DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis | ABNewswire

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Pfizer (PFE) Heads To ESMO With 45 Oncology Abstracts And Fresh Cancer Data

Trump administration has signed agreements with pharmaceutical companies Pfizer, Eli Lilly

Lupin Secures FDA Tentative Approval for Eliquis Generic, Targeting $3.3 Billion Market, ETPharma

Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO | Morningstar

Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition